Movement Alert｜INSILICO Rises 5.09% in Regular Trading, ISM6331 Granted FDA Fast Track Designation Plus Sector Recovery

Market Focus07-31

On July 31, INSILICO rose 5.09% in regular trading, trading at 44.52 HKD/share, with turnover of 43.21 million HKD. The stock rebounded after a cumulative decline of approximately 9% over the prior three trading sessions.

On the news front, the company's AI-driven pan-TEAD inhibitor ISM6331 was granted FDA Fast Track designation on July 29 for treating unresectable malignant pleural mesothelioma in adult patients who previously received anti-PD-1 antibody therapy and platinum-based chemotherapy. ISM6331 had already received FDA Orphan Drug designation in 2024. Additionally, the Phase 1 clinical data for ISM6331 has been accepted for oral presentation at the ESMO 2026 Annual Meeting scheduled for October 25 in Madrid. Meanwhile, the company's lead asset Rentosertib formally initiated its Phase 3 clinical trial on July 8 for idiopathic pulmonary fibrosis.

Within the Life Sciences Tools and Services sector, WUXI BIO up 1.53%, XTALPI up 2.33%, JOINN up 2.07%, GENSCRIPT BIO up 1.28%, WUXI APPTEC flat at 0%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145899210?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145899210","market":"us","top_or_hot":-1,"title":"Movement Alert｜INSILICO Rises 5.09% in Regular Trading, ISM6331 Granted FDA Fast Track Designation Plus Sector Recovery","media":"Market Focus","content":"<p><p>On July 31, INSILICO rose 5.09% in regular trading, trading at 44.52 HKD/share, with turnover of 43.21 million HKD. The stock rebounded after a cumulative decline of approximately 9% over the prior three trading sessions.</p><p>On the news front, the company's AI-driven pan-TEAD inhibitor ISM6331 was granted FDA Fast Track designation on July 29 for treating unresectable malignant pleural mesothelioma in adult patients who previously received anti-PD-1 antibody therapy and platinum-based chemotherapy. ISM6331 had already received FDA Orphan Drug designation in 2024. Additionally, the Phase 1 clinical data for ISM6331 has been accepted for oral presentation at the ESMO 2026 Annual Meeting scheduled for October 25 in Madrid. Meanwhile, the company's lead asset Rentosertib formally initiated its Phase 3 clinical trial on July 8 for idiopathic pulmonary fibrosis.</p><p>Within the Life Sciences Tools and Services sector, WUXI BIO up 1.53%, XTALPI up 2.33%, JOINN up 2.07%, GENSCRIPT BIO up 1.28%, WUXI APPTEC flat at 0%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜INSILICO Rises 5.09% in Regular Trading, ISM6331 Granted FDA Fast Track Designation Plus Sector Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜INSILICO Rises 5.09% in Regular Trading, ISM6331 Granted FDA Fast Track Designation Plus Sector Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-31 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 31, INSILICO rose 5.09% in regular trading, trading at 44.52 HKD/share, with turnover of 43.21 million HKD. The stock rebounded after a cumulative decline of approximately 9% over the prior three trading sessions.</p><p>On the news front, the company's AI-driven pan-TEAD inhibitor ISM6331 was granted FDA Fast Track designation on July 29 for treating unresectable malignant pleural mesothelioma in adult patients who previously received anti-PD-1 antibody therapy and platinum-based chemotherapy. ISM6331 had already received FDA Orphan Drug designation in 2024. Additionally, the Phase 1 clinical data for ISM6331 has been accepted for oral presentation at the ESMO 2026 Annual Meeting scheduled for October 25 in Madrid. Meanwhile, the company's lead asset Rentosertib formally initiated its Phase 3 clinical trial on July 8 for idiopathic pulmonary fibrosis.</p><p>Within the Life Sciences Tools and Services sector, WUXI BIO up 1.53%, XTALPI up 2.33%, JOINN up 2.07%, GENSCRIPT BIO up 1.28%, WUXI APPTEC flat at 0%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1145899210","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145899210","pubTimestamp":1785461603,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 31, INSILICO rose 5.09% in regular trading, trading at 44.52 HKD/share, with turnover of 43.21 million HKD. The stock rebounded after a cumulative decline of approximately 9% over the prior...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"走势警报|INSILICO 常规交易上涨 5.09%，ISM6331 获得 FDA 快速通道认证以及行业复苏","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"On July 31, INSILICO rose 5.09% in regular trading, trading at 44.52 HKD/share, with turnover of 43.21 million HKD. The stock rebounded after a cumulative decline of approximately 9% over the prior three trading sessions.On the news front, the company's AI-driven pan-TEAD inhibitor ISM6331 was granted FDA Fast Track designation on July 29 for treating unresectable malignant pleural mesothelioma in adult patients who previously received anti-PD-1 antibody therapy and platinum-based chemotherapy. ISM6331 had already received FDA Orphan Drug designation in 2024. Additionally, the Phase 1 clinical data for ISM6331 has been accepted for oral presentation at the ESMO 2026 Annual Meeting scheduled for October 25 in Madrid. Meanwhile, the company's lead asset Rentosertib formally initiated its Phase 3 clinical trial on July 8 for idiopathic pulmonary fibrosis.Within the Life Sciences Tools and Services sector, WUXI BIO up 1.53%, XTALPI up 2.33%, JOINN up 2.07%, GENSCRIPT BIO up 1.28%, WUXI APPTEC flat at 0%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145899210","isCrawlerRequest":true}